Skip to content

You are now leaving makena.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

You are now leaving makena.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue
Makena® (hydroxyprogesterone caproate injection)
makena care connection logo

On April 6, 2023, the U.S. Food and Drug Administration (FDA) issued a final decision ordering the withdrawal of the approval of Makena®. FDA has stated that it recognizes that a limited supply of these drugs has already been distributed, including to physicians’ offices and pharmacies. FDA acknowledges that some health care providers might continue to prescribe or administer that limited remaining supply to their patients. However, we recommend health care practitioners consider FDA’s conclusions.

If you have questions or concerns about receiving your therapy as prescribed, please consult with your healthcare provider. For any other Makena-related question, please call our Medical Information Call Center at +1-877-411-2510, Monday-Friday from 9:00 AM-7:00 PM EST.

Please see Full Prescribing Information for Makena.

This page will redirect to CovisPharma.com in 30 seconds.

PP-MKN-US-00714 08/23